<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114491</url>
  </required_header>
  <id_info>
    <org_study_id>22352</org_study_id>
    <nct_id>NCT00114491</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Affecting Aortic Valve Endothelium</brief_title>
  <official_title>Rosuvastatin Affecting Aortic Valve Endothelium - RAAVE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Pedro Hispano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Pedro Hispano</source>
  <brief_summary>
    <textblock>
      Recent studies support the hypothesis that aortic stenosis (AS) develops due to
      atherosclerosis affecting the aortic valve endothelium. The study’s aim was to assess
      Rosuvastatin on the hemodynamic progression and inflammatory markers of AS by treating
      low-density lipoprotein (LDL) in patients with AS according to the National Cholesterol
      Education Program Adult Treatment Panel III (NCEP-ATPIII) guidelines for one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Recent retrospective studies support the hypothesis that statins slow the
      progression of aortic stenosis. The aim of this study was to assess the effect of
      Rosuvastatin on hemodynamic progression of aortic stenosis by treating patients with aortic
      stenosis and elevated LDL-cholesterol for 18 months.

      Methods: We performed an open-label, prospective study evaluating 121 consecutive patients
      with asymptomatic moderate to severe aortic stenosis (AVA≥ 1.0 cm2), (mean age 73.7±8.9
      years; 57 men and 64 women), treated with and without Rosuvastatin according to the
      NCEP-ATPIII guidelines. Echocardiographic, serum lipid, and inflammatory markers were
      measured at baseline and every 6 months for 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>May 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic AS

          -  Normal ejection fraction

          -  Elevated LDL &gt;130 mg/dl

        Exclusion Criteria:

          -  Echocardiographic evidence of rheumatic mitral valve disease,

          -  Previous statin therapy,

          -  Congenital heart disease (bicuspid aortic valve),

          -  Subaortic obstruction,

          -  Creatinine ≥ 2,0 mg/dl (to avoid the potential confounder of an elevated serum
             [CaP04]),

          -  Evidence of liver disease,

          -  Greater than mild aortic regurgitation and previous aortic valve surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis M Moura</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pedro Hispano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Pedro Hispano</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <results_reference>
    <citation>Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005 Jun;91(6):806-10.</citation>
    <PMID>15894785</PMID>
  </results_reference>
  <results_reference>
    <citation>Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol. 2005 Feb 15;45(4):631-3.</citation>
    <PMID>15708716</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajamannan NM. Is it time for medical therapy for aortic valve disease? Expert Rev Cardiovasc Ther. 2004 Nov;2(6):845-54.</citation>
    <PMID>15500430</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aortic-valve disease. N Engl J Med. 2003 Aug 14;349(7):717-8.</citation>
    <PMID>12917318</PMID>
  </results_reference>
  <results_reference>
    <citation>Otto CM. Why is aortic sclerosis associated with adverse clinical outcomes? J Am Coll Cardiol. 2004 Jan 21;43(2):176-8.</citation>
    <PMID>14736433</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004 Sep 7;110(10):1180-2.</citation>
    <PMID>15353511</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003 May 6;107(17):2181-4. Epub 2003 Apr 28.</citation>
    <PMID>12719282</PMID>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2005</study_first_submitted>
  <study_first_submitted_qc>June 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2005</study_first_posted>
  <last_update_submitted>October 30, 2006</last_update_submitted>
  <last_update_submitted_qc>October 30, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2006</last_update_posted>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Statins</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

